SFA
REGN icon

Souders Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Souders Financial Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-414
Closed -$263K – 208
2025
Q1 		$263K Sell
414
-75
-15% -$51.6K 0.04% 160
2024
Q4 		$348K Sell
489
-278
-36% -$233K 0.05% 143
2024
Q3 		$806K Buy
767
+5
+0.7% +$5.56K 0.11% 110
2024
Q2 		$801K Buy
+762
New +$739K 0.12% 106

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Souders Financial Advisors's REGN Position: Q2 2025 in Review

Souders Financial Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 414 shares — an estimated $263K sold.

Souders Financial Advisors first reported a position in REGN in Q2 2024 and held it in 4 quarters. The position peaked at $806K in Q3 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

  • Souders Financial Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Souders Financial Advisors sold 414 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $263K.
  • Souders Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Souders Financial Advisors's Regeneron Pharmaceuticals position peaked at $806K in Q3 2024.
  • 1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Souders Financial Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.